WHO-EORTC classification for cutaneous lymphomas, Blood, vol.105, pp.3768-3785, 2005. ,
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), Blood, vol.110, pp.1713-1722, 2007. ,
Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression, Arch Dermatol, vol.139, pp.857-866, 2003. ,
Prise en charge des lymphomes T cutanés: recommandations du Groupe français d'étude des lymphomes cutanés, Ann Dermatol Venereol, vol.137, pp.611-621, 2010. ,
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome, Eur J Cancer, vol.42, pp.1014-1030, 2006. ,
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, vol.12, pp.1247-1252, 2007. ,
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action, J Invest Dermatol, vol.125, pp.1045-1052, 2005. ,
Histone deacetylases and cancer: causes and therapies, Nat Rev Cancer, vol.1, pp.194-202, 2001. ,
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for firstline therapy of advanced non-small-cell lung cancer, J Clin Oncol, vol.28, pp.56-62, 2010. ,
,
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study, J Thorac Oncol, vol.4, pp.522-526, 2009. ,
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome, J Clin Oncol, vol.30, pp.2204-2210, 2012. ,
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer, Br J Cancer, vol.104, pp.1828-1835, 2011. ,
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, vol.109, pp.31-39, 2007. ,
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J Clin Oncol, vol.25, pp.3109-3115, 2007. ,
, Common Terminology Criteria for Adverse Events (CT-CAE) Version, 2009.
,
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma, Clin Lymphoma Myeloma, vol.9, pp.412-416, 2009. ,
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma, J Dermatol, vol.39, pp.823-828, 2012. ,
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid x receptor activation by histone deacetylase inhibition, Leuk Lymphoma, vol.53, pp.1501-1508, 2012. ,
Histone deacetylase inhibitors: emerging mechanisms of resistance, Mol Pharm, vol.8, pp.2021-2031, 2011. ,
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor, Blood, vol.121, pp.4115-4125, 2013. ,